HV-107

HV-107 is a novel small molecule carbazole derivative and a potent inhibitor of the Rho GTPase Rac1. Developed by the University of Puerto Rico and the Universidad Central del Caribe, HV-107 is a derivative of the Rac inhibitor EHop-016, designed to mimic its active conformation with improved potency and reduced toxicity. It acts by blocking the interaction between Rac1 and its guanine nucleotide exchange factor (GEF) Vav2, thereby inhibiting Rac1 activation. In preclinical studies, HV-107 has demonstrated significant efficacy in reducing cell migration, invasion, and metastasis in triple-negative breast cancer (TNBC) models, with minimal toxicity to non-cancerous cells.

Other names

9-ethyl-9H-carbazole-3-carboxylic acid (2-morpholin-4-yl-pyridin-3-yl)-amide9-ethyl-N-(2-morpholinopyridin-3-yl)-9H-carbazole-3-carboxamide